Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Wegovy

  • Mounjaro and Wegovy demand helps Chemist4U sales double

    healthcare

    Increasing demand for weight-loss jabs such as Mounjaro and Wegovy has helped sales at the firm behind online pharmacy Chemist4U almost double. The Skelmersdale-based business has reported a turnover of £59.5m for the year to 30 September, 2024, according to new accounts filed with Companies House. The latest total comes after the firm behind Chemist4U [...]

    Sales at the company behind Chemist4U have doubled thanks to the demand for weight-loss drugs. (Photo Illustration by Scott Olson/Getty Images)
  • Is your business about to feel the Ozempic squeeze? 

    Opinion

    Reshaping stomachs with weightloss drugs like Ozempic likely means reshaping some markets (and probably your strategy), says Paul Armstrong Ozempic, Wegovy, and Mounjaro are driving a subtle but undeniable shift in obesity rates across the U.S, showing a 2 per cent drop so far. While it’s too soon to crown these drugs the cure-all, their [...]

    Four in 100 households in the UK now have at least one member using GLP-1, the active ingredient in weight-loss drugs like Ozempic.
  • Digital health firm explores London listing amid surge in demand for weight-loss jabs

    Healthcare

    Digital health business Reset Health is mulling a potential listing on London's stock market as it looks to pounce on the boom in demand for weight-loss jabs.

    Four in 100 households in the UK now have at least one member using GLP-1, the active ingredient in weight-loss drugs like Ozempic.
  • Ozempic and Wegovy: What happens when a drug goes viral?

    May 18, 2024

    Novo Nordisk's Wegovy and Ozempic have been heralded as the solution to the world's growing obesity problems. But when celebrities and influencers misuse them and start documenting their weight loss journeys online, should we take stock?

Trending Articles

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook